On Tuesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: CBOE Holdings, Inc. (NASDAQ:CBOE), XOMA Corporation (NASDAQ:XOMA), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT)
CBOE Holdings, Inc. (NASDAQ:CBOE), with shares declined -2.02%, closed at $58.25.
XOMA Corporation (NASDAQ:XOMA), with shares dropped -2.01%, settled at $3.90.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA), with shares dipped -4.65 %, and closed at $2.46.
Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT), plummeted -4.00%, and closed at $1.68.
Latest NEWS regarding these Stocks are depicted underneath:
CBOE Holdings, Inc. (NASDAQ:CBOE)
CBOE Holdings, Inc. (CBOE), declared that it plans to list options on the MSCI Emerging Markets Index (EEM) and the MSCI EAFE Index (EAFE) starting Tuesday, April 21. The declaration was made on March 11’s morning during a CBOE press briefing at the Futures Industry Association conference, took place in Boca Raton, Florida.
In December 2014, CBOE Holdings, Inc. declared it reached a licensing contract with MSCI Inc., a leading provider of investment decision support tools worldwide, to offer options trading on several MSCI Indexes. Under the contract, options on the MSCI Indexes will be solely listed for trading in the U.S. on the Chicago Board Options Exchange® (CBOE®). Options on the EEM and EAFE Indexes are the first of six MSCI Indexes planned to launch in 2015. Later this year, CBOE also plans to offer options on the MSCI ACWI Index, MSCI USA Index, MSCI World Index and the MSCI ACWI ex-USA Index.
CBOE Holdings, Inc., through its auxiliaries, operates as an options exchange and creator of listed options in the United States. The corporation provides marketplaces for trading options on various market indexes; futures on the VIX Index and other products; options on the stocks of individual corporations comprising equity options; and options on other exchange-traded products that comprise ETP options, such as exchange-traded funds and exchange-traded notes.
XOMA Corporation (NASDAQ:XOMA)
Formerly on March 11, XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, stated its operational highlights and financial results for the quarter and year ended December 31, 2014.
Recent Highlights:
- Advanced all gevokizumab clinical studies, counting initiating the Phase 3 EYEGUARD(TM)-US study in U.S. patients with Behcet’s disease uveitis and the Phase 3 study in patients with pyoderma gangrenosum.
- Accomplished enrollment of eight patients in the gevokizumab open-label proof of concept clinical trial in patients with active, non-infectious, anterior scleritis being conducted under Dr. Nida Sen’s leadership at The National Eye Institute (NEI). The study objectives were to evaluate the safety and possible efficacy of gevokizumab in patients with active scleral inflammation at baseline. Although the study is still ongoing, 6 of the 8 study participants had a positive response in the first 16 weeks of gevokizumab treatment, based on a standardized scale. The Corporation will be working with NEI to design a possible multi-center controlled trial in this difficult to treat condition.
- Successfully accomplished the Phase 1 clinical study of XOMA 358, a fully human, allosteric monoclonal antibody that inhibits both the binding of insulin to its receptor and downstream insulin signaling, and presented the data at ENDO 2015. XOMA 358 is being evaluated for the treatment of non-drug-induced, endogenous hyperinsulinemic hypoglycemia (low blood glucose caused by excessive insulin produced endogenously).
- Strengthened the Corporation’s financial position by raising $37.7 million, after deducting offering costs and out-of-pocket expenses, through the sale of units at a price of $4.94. Each unit comprises a share of ordinary stock and an accompanying warrant with a term of two years to purchase one additional share of ordinary stock at an exercise price of $7.90 per share.
- Renegotiated terms of the SERVIER loan contract. The loan now will be repaid in three annual payments, starting on January 15, 2016, and ending January 15, 2018, rather than being due in its entirety on January 15, 2016.
- Obtained a $20.0 million secured loan from Hercules Technology III, L.P., as lender, and associate of Hercules Technology Growth Capital, Inc., as agent; a portion of the proceeds from which were used to repay a portion of existing indebtedness with the remaining proceeds to be used for general corporate purposes.
- Declared the promotion of Thomas Burns to Chief Financial Officer and the retirement of Fred Kurland.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The corporation’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Formerly on March 12, Synta Pharmaceuticals Corp. (SNTA), stated financial results for the fourth quarter and year ended December 31, 2014 and offered an operational update.
Fourth quarter and full year 2014 financial results:
- There were no proceeds recognized in the fourth quarters of 2014 and 2013. There were no proceeds recognized for either the year ended December 31, 2014 or for the same period in 2013.
- Research and development expenses were $15.7 million for the fourth quarter in 2014, contrast to $20.0 million for the same period in 2013. Research and development expenses were $68.2 million for the year ended December 31, 2014, contrast to $71.9 million for the same period in 2013.
- General and administrative expenses were $4.2 million for the fourth quarter in 2014, contrast to $3.5 million for the same period in 2013. General and administrative expenses were $15.7 million for the year ended December 31, 2014, contrast to $15.7 million for the same period in 2013.
- The Corporation stated a net loss of $20.4 million or $0.19 per basic and diluted share in the fourth quarter of 2014, contrast to a net loss of $24.2 million or $0.31 per basic and diluted share for the same period in 2013. For the year ended December 31, 2014, the Corporation stated a net loss of $86.2 million or $0.87 per basic and diluted share, contrast to a net loss of $90.2 million or $1.27 per basic and diluted share for the same period in 2013.
- As of December 31, 2014, the Corporation had $97.7 million in cash, cash equivalents and marketable securities, contrast to $91.5 million as of December 31, 2013.
The Corporation anticipates its cash resources of about $97.7 million at December 31, 2014 will be sufficient to fund operations at least through the end of 2015. This estimate assumes no additional funding from new partnership contracts, equity financings or further sales under its ATM. The timing and nature of certain activities contemplated for 2015 will be conducted subject to the availability of sufficient financial resources.
Synta Pharmaceuticals Corp., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, counting cancer and chronic inflammatory diseases. The corporation has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development.
Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT)
Neptune Technologies & Bioressources, Inc. (NEPT), and Acasti Pharma Inc. (ACST), declared that on March 23, 2015 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) issued a favourable decision, confirming the validity of certain claims in Neptune’s ‘351 patent (U.S. Patent: 8,278,351) and triggering royalty payments to Neptune.
“This is a noteworthy milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US,” highlighted Jim Hamilton, President and CEO of Neptune. “The decision clearly supports the validity and enforceability of Neptune’s ‘351 composition of matter patent. Now that the positive decision has been rendered, we can turn our attention to building the industry and growing the krill oil market.”
“Our intellectual property (IP) is a fundamental and valuable asset,” highlighted Benoit Huart, Director Legal Affairs at Neptune. “The positive decision preserves strong IP protection for both our nutraceutical and pharmaceutical businesses and substantiates our IP procurement and enforcement strategy. Aker and Enzymotec may appeal the decision. Regardless, the strength of our patent estate has once again been recognized. We will continue to enforce and build upon it to ensure we have long lasting and comprehensive protection, while preventing others from importing into and selling infringing products wherever we have valid patents.”
Neptune Technologies & Bioressources Inc., a biotechnology corporation, focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
